T regs are back – promising to do for autoimmunity what CAR Ts have done in cancer
The following article was published in BioCentury Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new…...
Read MoreQuell Therapeutics named a “Fierce 15“ Company by FierceBiotech
London, 23 September 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private…...
Read MoreQuell Therapeutics, founded by Syncona Ltd, appoints Chief Executive
Building a team of leading experts in the field of Regulatory T cell-based therapy and biology London, 13 June 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces the appointment of Iain McGill,…...
Read More